Andrea has over 20 years’ experience as a state registered clinical scientist in NHS genetic diagnostic laboratories. Andrea’s innovation, SAPIENTIA™, is a genome analytics software enabling healthcare professionals to interrogate the human genome for pathogenic mutations likely to be the cause of a patient’s inherited disease.
This technology, developed from the Deciphering Developmental Disorders (DDD) translational research study, is particularly relevant for rare diseases, 75% of which have a genetic cause that manifests during childhood.
On average it takes over five years for patients to receive a diagnosis; by utilising genome and clinical data, SAPIENTIA™ facilitates the rapid identification and interpretation of disease causing variants resulting in a speedier diagnosis and better clinical decision support for patients with rare genetic disease.
Andrea is Head of Clinical Services, Congenica, a company founded on the world-leading DDD genomic technology pioneered at the Wellcome Trust Sanger Institute and the Department of Health.
Anna is a Specialist Registrar in Psychiatry at Cambridge, and Implementation Lead for the i-Thrive partnership, involving the Anna Freud Centre, the Tavistock & Portman NHS Foundation Trust, the Dartmouth Centre for Health Care Delivery Science (US) and UCLPartners. She is also an Implementation Fellow at the Anna Freud Centre.
Anna is diffusing i-Thrive, a combinatorial innovation bringing together a new model of care for child and adolescent mental health, Thrive (Wolpert et al), with two validated tools supporting shared decision making, CollaboRATE and Option Grids(r) (Elwyn, G. et al).
Anna is excited at the prospect of NIA support and the opportunity to learn from colleagues. She aims to implement i-Thrive effectively in a range of local health economies, developing approaches for application to other whole-system transformations.
Anna brings frontline healthcare experience as a trainee psychiatrist and her academic work, including neuroscience research at Harvard University and a PhD, which she is undertaking at UCL on delivering high quality, efficient health care.
Anne joins the NIA from the Netherlands where she is founder of PxHealthcare. Anne has devoted much of her international career to the development of more effective, personalised drug treatments and diagnostic tools.
Through Anne’s innovation, OWise, patients record in real time the experiences they have as they undergo treatment for cancer including side-effects and overall quality of life. Through the application, they then receive information about their conditions and wellbeing as well as giving tips as to topics to discuss with their doctor.
For clinicians and researchers, OWise offers a wealth of data as to the value of treatments patients are receiving and can therefore support decision-making about what treatments are offered to patients.
Anne aims to ensure OWise is available for breast cancer patients across the UK and in the longer term to extend it to other types of cancer.
Ben is an NHS general dental practitioner working in York and is passionate about ensuring all patients have and maintain good oral health throughout their lives to avoid the need for invasive and sometimes expensive dental treatment.
He has developed Brush DJ – the only evidence-based, free, NHS approved app that motivates an effective self-care oral hygiene routine by playing two minutes of the user’s music – making toothbrushing fun! Ensuring children adopt good oral hygiene from a young age will help prevent a number of dental diseases for a lifetime.
Ben’s ambition is to help all children to grow up free from dental decay and the consequent need for possibly distressing treatment under general or local anaesthetic. Brush DJ aims to do this by motivating an enjoyable, evidence-based oral hygiene self-care routine that is part of everyday life and is available to all children and young people, anywhere.
Bernadette was the first nurse in the NHS to be appointed as a multiple sclerosis nurse consultant in 2003 and was awarded an MBE for her work. She has developed and spearheaded NeuroResponse – a new technology that gives patients with neurological conditions more control over the care they receive.
It includes a telephone triage/advice line staffed by specialist nurses, email advice services for GPs wishing to contact a Consultant Neurologist, and a video clinic linking a specialist’s neurology team with the patient and local clinical team in the patient’s community. Using the expert Nurse telephone Triage service, patients and staff can discuss physical, mental, and social care needs, agree plans and share information. The Expert Nurse can triage the patient – patient anxiety is reduced, confidence increases, and treatment interventions are timely.
During the NIA programme, Bernadette plans to scale up the expert telephone component of NeuroResponse for patients with multiple sclerosis across a number of regions and then adapt it for other neurological conditions.
Dharmesh’s innovation is called EPISCISSORS-60 which are patented fixed angle scissors that take away human error in estimating episiotomy angles during childbirth. This innovation reduces the risk of complications associated with standard practice episiotomies which can cause obstetric anal sphincter muscle injuries and have a devastating impact on the quality of a new mother’s life.
EPISCISSORS-60 is already being used in 15 UK hospitals and Dharmesh’s ambition for the NIA programme is to accelerate diffusion of the use of EPISCISSORS-60 into UK clinical practice.
Dharmesh is director of Medinvent and Consultant Obstetrician and Gynaecologist at the Royal Bournemouth Hospital, Bournemouth.
Francis is the only UK-based employee of US company AliveCor where he has been EU General Manager since January 2013 and set up the local affiliate, AliveCor Ltd. AliveCor has developed the first mobile heart monitor that allows individuals to detect, monitor and manage heart arrhythmias with automatic analysis. Called the AliveCor® Mobile ECG, the device can capture electrocardiogram (ECG) recordings of the heart anytime, anywhere providing instant feedback.
Francis’ ambition is to transform the diagnostic pathway particularly for sufferers of undiagnosed palpitations and other cardiac symptoms. AliveCor® Mobile ECG enables patients to take an ECG at home or on-the-go, to know when their ECG is normal or not and instantly know if atrial fibrillation (AF), a leading cause of stroke, is detected in the ECG. Also, to easily and remotely share their ECGs with their doctor, thus moving this diagnostic service out of secondary care hospitals and into the community.
Lloyd is a clinical psychologist by background. He brings Patients Know Best to the NIA programme, an innovation that enables patients to hold all their medical information in a single record owned by them.
This single record puts the patient at the centre of their care, empowering their health network and challenging traditional models of care. With the patient able to invite anyone they wish to their profile, they can construct a strong and comprehensive care network best suited to them, made up of diverse clinical teams and friends and family able to support at-home care.
Lloyd’s aspiration is that anybody in the UK will have access to their own healthcare data, be able to share it with whomever they please, and to participate proactively with the record to manage and lead their own care.
Maryanne is Clinical Research Fellow at the Queen Elizabeth Hospital, Kings Lynn and Addenbrooke’s University Hospital, Cambridge. She is currently undertaking a Doctorate at the University of Cambridge relating to Patient Safety in the NHS and is specifically researching the use of innovation to prevent never events or serious adverse events.
Maryanne’s innovation is the Non-injectable arterial connector (NIC), which improves the safety and care of all patients requiring an arterial line in operating theatres and intensive care. Although rare, when wrong route drug administration occurs, it has the potential to cause serious damage to the vessel and surrounding tissue. The NIC enables conventional arterial line sampling, but eradicates the potential to accidentally administer medication into the arterial line and is a definitive solution to the problem.
The NIC has been trialled by 11 trusts in the East of England and Maryanne hopes to implement the NIC nationally through the NIA programme.
HealthUnlocked is a peer-to-peer social support network for health. It links together patients, carers and health advocates with professional and accredited organisations to share experiences of health conditions, symptoms, treatments, and health services.
These are catalogued in an intelligent database which signposts relevant content to people based on their profile. By finding others with similar health backgrounds patients can take on day-to-day health concerns together.
Matthew is an ex-Orthopaedic Registrar and says he is continually excited by the generational opportunity to change the world of health with well-made web technology. His ambition whilst on the NIA Programme is to bring the explosive growth and patient engagement HealthUnlocked has cultivated over the last four years and connect it to where it will add most impact across the NHS.
Neil has co-developed a diagnostic pathway to detect significant but asymptomatic chronic liver disease at a critical stage in which it can either progress or reverse. The pathway combines both the identification of patients at risk of chronic liver diseases and utilises proven diagnostic tests to detect and stratify the risk; thirdly it aims to provide a seamless pathway between primary and secondary care. He aims to show that the pathway can be implemented at other sites across the East Midlands before scaling it nationally.
Neil’s ambition for the programme is to gain a greater understanding of how to implement genuine innovation within the NHS infrastructure in a timely manner.
Neil is a Clinical Associate Professor in Hepatology, University of Nottingham and Consultant Hepatologist, at Nottingham University Hospitals.
Paul founded Nervecentre Software in 2010 to address the absence of strong clinical collaboration tools in the market. His aim was to improve hospital communication that traditionally leads to significant delays in patient care and can result in huge inefficiencies.
Nervecentre Software provides a whole hospital platform that delivers electronic observations, handover, task management and clinical assessments; and allows governance and escalation management to be added to any hospital process.
Paul has a background in technical roles and sales and business development roles for blue chip organisations such as Cisco Systems. Paul applied to become a Fellow because he wants to drive significant patient safety and efficiency benefits across UK hospitals, which is essential in achieving a sustainable NHS – Nervecentre has the potential to do this.
Penny has pioneered the use of health coaching in the NHS to improve outcomes for people with long-term conditions. She has co-designed and led with colleagues from Health Education East of England, Health Coaching training for clinicians so they can enable people to gain the knowledge, skills and confidence to become more active participants in their care, reach self-identified goals and adopt more healthy behaviours. Health coaching is a person-centred process and widely applicable to all long-term conditions, covering prevention, decision making, self-management and medication compliance.
Evaluation shows that health coaching can have a transformative impact on clinicians’ practice and can make their work more fulfilling. It provides clinicians with new mindsets and communication techniques that help patients take control of their condition to improve their health and quality of life. Rolled out nationally, health coaching has the potential not only to improve patient outcomes, but also to reduce costs and address inequalities, as it helps clinicians to support more vulnerable patients.
Peter is CEO and co-founder of Big Health, a company that develops personalised behavioural medicine programmes. Peter’s innovation was developed following his own experience of insomnia and the difficulty he experienced in being able to access evidence-based non-drug help via the NHS.
Sleepio is a digital sleep improvement programme (available via web and mobile), clinically proven to help overcome even long-term poor sleep. Over a number of weekly sessions, users are taught proven cognitive and behavioural techniques by a virtual sleep expert to help them get their schedule, thoughts and lifestyle into shape. But the impact goes beyond sleep – Sleepio has helped 65% of patients referred to it via an IAPT service move to recovery from depression and anxiety.
Peter’s long term ambition is for Sleepio to be widely available throughout the NHS as a smart, destigmatised way to help people improve their mental health.
Peter is a proven innovator having developed ten devices, three of which have been brought to market. His innovation on the NIA programme is the PneuX Pneumonia Prevention System, which is designed to stop ventilator-associated pneumonia (VAP), the leading cause of hospital-acquired mortality in Intensive Care Units. The innovation is a cuffed ventilation tube and an electronic cuff monitoring and inflating device which prevents leakage of bacterial laden oral and stomach contents to the lung – a problem associated with standard tubes.
Peter says his experience has shown that coming up with the idea is not the challenge but scaling a great innovation across the NHS involves many challenges. His ambition for the NIA is to overcome the barriers to diffusion.
Peter is Consultant in Anesthesia and Director of Critical Care at the Queen Elizabeth Hospital, Kings Lynn.
Piers has been working to increase the numbers of patients taking part in dementia research. One of the big difficulties researchers face today is recruiting participants for their studies. At the same time, many people are looking for studies to contribute to and take part in, but do not know where to find out about them.
Join Dementia Research allows people to register their interest in participating in dementia research and be matched to suitable studies. This innovation benefits people affected by dementia, and researchers by increasing the speed and reducing the cost of research. It has the potential to drive evidence-based improvements in prevention, diagnosis and treatment of dementia into practice more quickly – and to be generalised to other conditions.
One of his ambitions through the NIA programme is to recruit 100,000 people to register on Join Dementia Research.
Piers has led the development of Join Dementia Research for the past five years and is based at University College London.
Simon has developed myCOPD: an IT patient self-management system for Chronic Obstructive Pulmonary Disease (COPD). This is a web based and iOS application that helps patients manage their condition more effectively. The platform interfaces with a clinician dashboard to monitor and manage their patients remotely at an individual and population level.
The platform can also be used by local health care providers and CCGs to monitor exacerbation burdens in real-time and review potential inequalities in health care to plan support services effectively.
Simon is an innovation and respiratory consultant at Portsmouth Hospital and also founder of company my mhealth which utilises mobile technology to provide patients with sophisticated health support information, and clinicians/organisations with tools to manage their populations more effectively.